🇺🇸 FDA
Pipeline program

Sarilumab

2018P002128

Phase 2 small_molecule terminated

Quick answer

Sarilumab for Morphea, Plaque Form is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Morphea, Plaque Form
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials